论文部分内容阅读
目的探讨联合检测血清糖类抗原125(CA125)、糖类抗原72-4(CA72-4)和糖类抗原19-9(CA19-9)对卵巢癌的临床应用价值。方法采用电化学发光法测定卵巢癌患者68例,卵巢良性肿瘤58例及80例健康女性体检者血清。结果卵巢癌组CA125、CA72-4和CA19-9水平和敏感性显著高于卵巢良性肿瘤组和正常对照组(p<0.01),CA125、CA72-4和CA19-9敏感性分别为79.3%、65.5%、44.8%,联合检测CA125和CA72-4的敏感性为86.2%;联合检测CA125和CA19-9的敏感性为81.0%,联合检测CA125、CA72-4和CA19-9的敏感性达到91.4%。结论血清CA125、CA72-4和CA19-9联合检测对卵巢癌的诊断有重要的临床应用价值。
Objective To investigate the clinical value of combined detection of serum carbohydrate antigen 125 (CA125), carbohydrate antigen 72-4 (CA72-4) and carbohydrate antigen 19-9 (CA19-9) in ovarian cancer. Methods The serum of 68 patients with ovarian cancer, 58 patients with benign ovarian tumor and 80 healthy women were detected by electrochemiluminescence. Results The levels and sensitivity of CA125, CA72-4 and CA19-9 in ovarian cancer group were significantly higher than those in benign ovarian tumor group and normal control group (p <0.01). The sensitivity of CA125, CA72-4 and CA19-9 were 79.3% 65.5%, 44.8%. The sensitivity of combined detection of CA125 and CA72-4 was 86.2%. The sensitivity of combined detection of CA125 and CA19-9 was 81.0%. The sensitivity of combined detection of CA125, CA72-4 and CA19-9 was 91.4 %. Conclusion Serum CA125, CA72-4 and CA19-9 joint detection of ovarian cancer diagnosis has important clinical value.